表紙
市場調査レポート

タンパク質治療薬の世界市場 (2016〜2020年)

Global Protein Therapeutics Market 2016-2020

発行 TechNavio (Infiniti Research Ltd.) 商品コード 345849
出版日 ページ情報 英文 130 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
タンパク質治療薬の世界市場 (2016〜2020年) Global Protein Therapeutics Market 2016-2020
出版日: 2015年11月25日 ページ情報: 英文 130 Pages
概要

世界のタンパク質治療薬市場は2015〜2020年にかけて、8%の年平均成長率 (CAGR) で成長する見通しです。特に、市場の55%を占めるモノクローナル抗体の需要増大が、市場全体の成長を促進しています。高額な治療費を抑制するために世界各国で医療費償還制度の整備が進められていることも、市場成長の一因となっています。地域別に見ると、北米が55%の市場シェアを有しています。一方、市場は非常に細分化されており、多数の企業が激しい競争を展開していますが、今後は企業合併・買収 (M&A) により小規模な企業の淘汰が進むものと思われます。

当レポートでは、世界のタンパク質治療薬市場について分析し、製品の概要や市場構造、市場規模の動向 (今後5年間の予測値)、製品種類別および治療分野別・地域別の詳細動向、市場の促進・抑制要因とその影響力、主要企業のプロファイル、今後の市場機会などを調査・推計しております。

第1章 エグゼクティブ・サマリー

  • 分析結果の概略

第2章 分析範囲

  • 分析概要
  • 大手ベンダーの主要製品

第3章 市場分析の手法

  • 分析手法
  • 経済指標

第4章 イントロダクション

  • 市場動向の概略

第5章 市場環境

  • 市場概要
  • 市場規模とその予測
  • ファイブフォース分析

第6章 製品種類別の市場区分

第7章 世界のモノクローナル抗体薬市場

  • イントロダクション
  • 市場概要
  • 市場促進要因
  • 市場の課題
  • 市場動向
  • ベンダー情報

第8章 世界のインスリン市場

第9章 世界のエリスロポエチン市場

第10章 世界のヒト成長ホルモン市場

第11章 治療領域別の市場区分

  • 代謝・内分泌障害
  • 造血
  • 肥満症
  • がん
  • 自己免疫疾患
  • 感染症
  • タンパク質ワクチン

第12章 タンパク質の機能別の市場区分

  • 酵素活性・調整活動
  • 特殊標的活動
  • ワクチン
  • タンパク質診断

第13章 地域区分

  • 世界のタンパク質治療薬市場:地域別の詳細動向 (今後6年間分)
  • 南北アメリカ市場
  • 欧州・中東・アフリカ地域 (EMEA) 市場
  • アジア太平洋地域市場

第14章 市場促進要因

  • モノクローナル抗体の需要増大
  • 良好な医療費償還政策
  • 慢性疾患の有病者数の増加
  • 有望な薬剤パイプライン
  • 活発な製品開発

第15章 促進要因の影響力

第16章 市場の課題

  • ベストセラー医薬品の特許満了
  • 厳格な規制
  • 治療費の高さ
  • 激しい市場競争
  • 副作用のリスク

第17章 促進要因・課題の影響力

第18章 市場の動向

  • 患者支援プログラム
  • 戦略的な事業提携
  • 標的療法の誕生
  • 未開拓市場への関心のシフト
  • 一般社会での知名度の上昇

第19章 ベンダー環境

  • 競争シナリオ
  • 市場シェア分析
  • その他の有力ベンダー

第20章 主要ベンダーの分析

  • AbbVie
  • Amgen
  • F.Hoffmann-La Roche
  • Johnson & Johnson
  • Merck Serono
  • Novo Nordisk

第21章 付録

  • 略語集

第22章 Technavioについて

図表一覧

目次
Product Code: IRTNTR8020

Market outlook of the protein therapeutics market

Technavios market research analyst predicts the global protein therapeutics market to grow steadily at a CAGR of 8% during the forecast period. Increased demand for and use of monoclonal antibodies is expected to drive the growth of the protein therapeutics market as it accounts for more than half of the protein therapeutics market. The monoclonal antibodies can be prepared specific to any cell surface or extracellular target. These antibodies are being used in radioimmunotherapy and antibody-directed enzyme prodrug therapy. Monoclonal antibodies are also used in the formulation of various biopharmaceutical drugs for the treatment of different diseases such as cancer, rheumatoid arthritis, multiple sclerosis, and UC.

The availability of favorable reimbursement policies in this market is expected to boost the market growth during the forecast period. Protein therapeutics are expensive and cannot be afforded by all, but reimbursement of the diagnostic kits and biologic drugs are expected to fuel the market during the forecast period. Plans like the public reimbursement programs reduce the financial burden of treatments. The reimbursement status of drugs varies from region to region, with factors such as lack of cost-effectiveness impeding the coverage.

Product segmentation and analysis of the protein therapeutics market

  • Monoclonal antibodies
  • Erythropoietin
  • Insulin
  • Human growth hormone
  • Interferons
  • Blood clotting factor
  • G-CSF
  • Follicle stimulating hormone

The monoclonal antibodies segment dominated the market during 2015, with a market share of 55%. An increase in the prevalence of cancer and autoimmune diseases, increase in research activities, and increased technological advancement in the development of next-generation antibodies are the main factors fueling the growth of this segment.

Geographical segmentation and analysis of the protein therapeutics market

  • Americas
  • APAC
  • EMEA

The Americas accounted for 48% of the market share during 2015 and is expected to grow at a CAGR of 7% during the forecast period. The promising public health approaches by the government, growing incidence, and an increase in regulatory support for the development of protein therapeutics are the primary drivers for the market growth in this region.

Competitive landscape and key vendors

The global protein therapeutics market is highly fragmented due to the presence of numerous small and large vendors. The vendors in the market compete on the basis of price, quality, and innovation. Competition among the vendors has led an increased number of M&A, wherein smaller entities are being acquired by, or are being merged with, major players.

The leading vendors in the market are -

  • AbbVie
  • Amgen
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Merck
  • Novo Nordisk

Other prominent vendors in the market include Anhui Anke Biotechnology, AstraZeneca, Baxter International, Biocon, Biodel, Biogenomics, BioPartners, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, Chugai Pharmaceutical, Diamyd Medical, Diasome Pharmaceuticals, DiaVacs, Dynavax Technologies, Eli Lilly, Ferring Pharmaceuticals, Generex Biotechnology, GeneScience Pharmaceuticals, Hualan Biological Engineering, Intas Pharmaceuticals, Ipsen, JCR Pharmaceuticals, Kyowa Hakko Kirin, Lexicon Pharmaceuticals, LG Life Sciences, Macrogenics, MannKind, Oramed Pharmaceuticals, Osiris Therapeutics, Pfizer, Sandoz International, Sanofi, Teva Pharmaceutical Industries, Thermalin Diabetes, Tolerion, Wockhardt, and XOMA.

Key questions answered in the report include

  • What will the market size and the growth rate be in 2020
  • What are the key factors driving the global protein therapeutics market
  • What are the key market trends impacting the growth of the protein therapeutics market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the vendors in the global protein therapeutics market
  • Trending factors influencing the market shares of the Americas, APAC, and EMEA
  • What are the key outcomes of the five forces analysis of the protein therapeutics market

Technavio also offers customization on reports based on specific client requirement.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 06: Market segmentation by product type

PART 07: Global monoclonal antibody drugs market

  • Introduction
  • Market overview
  • Market drivers
  • Market challenges
  • Market trends
  • Vendors of global monoclonal antibody drugs market

PART 08: Global insulin market

  • Introduction
  • Market overview
  • Market drivers
  • Market challenges
  • Market trends
  • Insulin market in Europe
  • Vendors of global insulin market

PART 09: Global erythropoietin market

  • Introduction
  • Market overview
  • Market drivers
  • Market challenges
  • Market trends
  • Erythropoietin market in Japan
  • Vendors of global erythropoietin market

PART 10: Global human growth hormone market

  • Introduction
  • Market overview
  • Market drivers
  • Market challenges
  • Market trends
  • Vendors of global human growth hormone market

PART 11: Market segmentation by therapy area

  • Metabolic and endocrine disorders
  • Hematopoiesis
  • Fertility
  • Cancer
  • Autoimmune diseases
  • Infectious diseases
  • Protein vaccine

PART 12: Market segmentation by protein function

  • Enzymatic and regulatory activity
  • Special targeting activity
  • Vaccines
  • Protein diagnostics

PART 13: Geographical segmentation

  • Global protein therapeutics market by geographical segmentation 2015-2020
  • Protein therapeutics market in Americas
  • Protein therapeutics market in EMEA
  • Protein therapeutics market in APAC

PART 14: Market drivers

  • Increased demand for monoclonal antibodies
  • Availability of favorable reimbursement policies
  • Increasing prevalence of chronic diseases
  • Promising drug pipeline
  • Frequent innovations

PART 15: Impact of drivers

PART 16: Market challenges

  • Patent expiration of top-selling drugs
  • Stringent regulations
  • High cost of therapy
  • Fierce market competition
  • Risk of side effects

PART 17: Impact of drivers and challenges

PART 18: Market trends

  • Patient assistance programs
  • Strategic alliances
  • Emergence of targeted therapies
  • Shifting focus toward untapped markets
  • Increase in public awareness

PART 19: Vendor landscape

  • Competitive scenario
  • Market share analysis 2015
  • Other prominent vendors

PART 20: Key vendor analysis

  • AbbVie
  • Amgen
  • F.Hoffmann-La Roche
  • Johnson & Johnson
  • Merck Serono
  • Novo Nordisk

PART 21: Appendix

  • List of abbreviations

PART 22: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Global protein therapeutics market 2015-2020 ($ billions)
  • Exhibit 03: Five forces analysis
  • Exhibit 04: Segmentation of global protein therapeutics market by product type
  • Exhibit 05: Global protein therapeutic market segment by product type based on revenue, 2015
  • Exhibit 06: Top-selling monoclonal antibodies based on revenue, 2014 ($ billions)
  • Exhibit 07: Global monoclonal antibody market 2015-2020 ($ billions)
  • Exhibit 08: Global human insulin market 2015-2020 ($ billions)
  • Exhibit 09: Insulin market in Europe 2015-2020 ($ billions)
  • Exhibit 10: Globally approved erythropoietin biosimilars
  • Exhibit 11: Global erythropoietin market 2015-2020 ($ billions)
  • Exhibit 12: Erythropoietin market in Japan 2015-2020 ($ millions)
  • Exhibit 13: Global human growth hormone market 2015-2020 ($ billions)
  • Exhibit 14: Segmentation of global protein therapeutics market by therapy area
  • Exhibit 15: Segmentation of global protein therapeutics market by protein function
  • Exhibit 16: Global protein therapeutics market by geography, 2015
  • Exhibit 17: Global protein therapeutics market revenue by geography 2015-2020 ($ billions)
  • Exhibit 18: Protein therapeutics market in Americas 2015-2020 ($ billions)
  • Exhibit 19: Protein therapeutics market in EMEA 2015-2020 ($ billions)
  • Exhibit 20: Protein therapeutics market in APAC 2015-2020 ($ billions)
  • Exhibit 21: Monoclonal antibody approvals by FDA and EMA from 2010-2014
  • Exhibit 22: Impact of drivers
  • Exhibit 23: Impact of drivers and challenges
  • Exhibit 24: Roche: YoY growth and revenue generated from net product sales of Actemra 2011-2014 ($ millions)
  • Exhibit 25: Roche: YoY growth and revenue generated from net product sales of Avastin 2011-2014 ($ millions)
  • Exhibit 26: Roche: YoY growth and revenue generated from net product sales of Herceptin 2011-2014 ($ millions)
  • Exhibit 27: Roche: Revenue generated from net product sales of Kadcyla 2013-2014 ($ millions)
  • Exhibit 28: Roche: YoY growth and revenue generated from net product sales of Lucentis 2011-2014 ($ millions)
  • Exhibit 29: Roche: YoY growth and revenue generated from net product sales of MabThera/Rituxan 2011-2014 ($ millions)
  • Exhibit 30: Roche: YoY growth and revenue generated from net product sales of Mircera 2011-2014 ($ millions)
  • Exhibit 31: Roche: YoY growth and revenue generated from net product sales of NeoRecorm/Epogin 2011-2014 ($ millions)
  • Exhibit 32: Roche: YoY growth and revenue generated from net product sales of Pegasys 2011-2014 ($ millions)
  • Exhibit 33: Roche: YoY growth and revenue generated from net product sales of Perjeta 2012-2014 ($ millions)
  • Exhibit 34: Roche: YoY growth and revenue generated from net product sales of Pulmozyme 2011-2014 ($ millions)
  • Exhibit 35: Novo Nordisk: Revenue generated from net product sales of new-generation insulins 2013-2014 ($ millions)
  • Exhibit 36: Novo Nordisk: YoY growth and revenue generated from net product sales of Levemir 2011-2014 ($ millions)
  • Exhibit 37: Novo Nordisk: YoY growth and revenue generated from net product sales of NovoRapid/NovoLog 2011-2014 ($ millions)
  • Exhibit 38: Novo Nordisk: YoY growth and revenue generated from net product sales of NovoMix 2011-2014 ($ millions)
  • Exhibit 39: Novo Nordisk: YoY growth and revenue generated from net product sales of human insulins 2011-2014 ($ millions)
  • Exhibit 40: Novo Nordisk: YoY growth and revenue generated from net product sales of NovoSeven 2011-2014 ($ millions)
  • Exhibit 41: Novo Nordisk: YoY growth and revenue generated from net product sales of Norditropin 2011-2014 ($ millions)
  • Exhibit 42: Amgen: YoY growth and revenue generated from net product sales of Aranesp 2011-2014 ($ millions)
  • Exhibit 43: Amgen: YoY growth and revenue generated from net product sales of Enbrel 2011-2014 ($ millions)
  • Exhibit 44: Amgen: YoY growth and revenue generated from net product sales of EPOGEN 2011-2014 ($ millions)
  • Exhibit 45: Amgen: YoY growth and revenue generated from net product sales of Neulasta 2011-2014 ($ millions)
  • Exhibit 46: Amgen: YoY growth and revenue generated from net product sales of NEUPOGEN 2011-2014 ($ millions)
  • Exhibit 47: Amgen: YoY growth and revenue generated from net product sales of Vectibix 2011-2014 (excluding Japan) ($ millions)
  • Exhibit 48: Amgen: YoY growth and revenue generated from net product sales of XGEVA 2011-2014 ($ millions)
  • Exhibit 49: Amgen: YoY growth and revenue generated from net product sales of Prolia 2011-2014 ($ millions)
  • Exhibit 50: AbbVie: YoY growth and revenue generated from net product sales of HUMIRA 2011-2014 ($ millions)
  • Exhibit 51: AbbVie: YoY growth and revenue generated from net product sales of Synagis 2011-2014 ($ millions)
  • Exhibit 52: AbbVie: YoY growth and revenue generated from net product sales of Lupron 2011-2014 ($ millions)
  • Exhibit 53: Johnson & Johnson: YoY growth and revenue generated from net product sales of Procrit 2011-2014 ($ millions)
  • Exhibit 54: Johnson & Johnson: YoY growth and revenue generated from net product sales of Remicade 2011-2014 ($ millions)
  • Exhibit 55: Johnson & Johnson: YoY growth and revenue generated from net product sales of Simponi 2011-2014 ($ millions)
  • Exhibit 56: Johnson & Johnson: YoY growth and revenue generated from net product sales of Stelara 2011-2014 ($ millions)
  • Exhibit 57: Merck: YoY growth and revenue generated from net product sales of Erbitux except US and Canada 2011-2014 ($ millions)
  • Exhibit 58: Merck: YoY growth and revenue generated from net product sales of Pegintron 2011-2014 ($ millions)
  • Exhibit 59: Merck: YoY growth and revenue generated from net product sales of Remicade 2011-2014 ($ millions)
  • Exhibit 60: Merck: YoY growth and revenue generated from net product sales of Simponi 2011-2014 ($ millions)
  • Exhibit 61: AbbVie: Product segmentation by revenue 2014
  • Exhibit 62: AbbVie: Product segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 63: AbbVie: Geographical segmentation by revenue 2014
  • Exhibit 64: Amgen: Business segmentation by revenue 2014
  • Exhibit 65: Amgen: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 66: Amgen: Geographical segmentation by revenue 2014
  • Exhibit 67: Roche: Business segmentation by revenue 2014
  • Exhibit 68: Roche: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 69: Roche: Geographical segmentation by revenue 2014
  • Exhibit 70: Johnson & Johnson: Business segmentation
  • Exhibit 71: Merck Serono: Product segmentation 2014
  • Exhibit 72: Merck Serono: Geographical segmentation by revenue 2014
  • Exhibit 73: Novo Nordisk: Business segmentation by revenue 2014
  • Exhibit 74: Novo Nordisk: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 75: Novo Nordisk: Geographical segmentation by revenue 2014
  • Exhibit 76: Novo Nordisk: R&D expenditure 2014
Back to Top